Welcome to our dedicated page for Pelthos Therapeutics SEC filings (Ticker: PTHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pelthos Therapeutics Inc. (PTHS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret them. As a Nevada-incorporated biopharmaceutical company listed on the NYSE American, Pelthos files a range of documents with the U.S. Securities and Exchange Commission that describe its business, governance, and financial obligations.
Key filings include Form 8-K current reports, where Pelthos discloses material events such as financing transactions, product acquisitions, and governance changes. Recent 8-K filings describe a senior secured term loan facility with Horizon Technology Finance Corporation intended to support commercialization of ZELSUVMI and the launches of Xepi and Xeglyze, an asset purchase agreement for the Xeglyze head lice treatment, and a securities purchase agreement for senior secured convertible notes used to fund the acquisition and planned relaunch of Xepi and to accelerate ZELSUVMI commercialization.
Other 8-K items and the company’s definitive proxy statement on Schedule 14A provide detail on board composition, director compensation policies, annual meeting proposals, and shareholder voting results. These documents outline Pelthos’ governance structure, committee responsibilities, and the terms under which directors and executives are compensated and indemnified.
On Stock Titan, investors can review Pelthos’ periodic reports (such as Forms 10-K and 10-Q when filed) for information on revenue from ZELSUVMI, operating expenses, cash position, and risk factors related to its commercial dermatology portfolio and financing arrangements. Form 4 and related insider transaction reports, when available, show equity dealings by directors and officers, offering additional insight into insider alignment.
AI-driven summaries on this page highlight the most important points from lengthy filings, such as covenants in loan agreements, conversion terms in convertible notes, and implications of mergers and name changes. Real-time updates from EDGAR ensure that new Pelthos filings—whether related to financings, acquisitions, or governance—are quickly reflected, while the AI layer helps users understand how each document fits into the company’s broader strategy around ZELSUVMI, Xepi, and Xeglyze.
Malamut Richard reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Richard Malamut filed an amended Form 4 to reclassify previously reported equity awards. The filing reports grants of 6,450, 19,108, and 2,454 shares of Common Stock at a price of $0.00 per share, reflecting restricted stock units (RSUs) issued under the company’s 2023 Equity Incentive Plan.
Each RSU represents the right to receive one share of Common Stock and vests in equal quarterly installments over three years, contingent on continued board service. The share amounts have been adjusted for the company’s 1-for-10 reverse stock split effective July 1, 2025. Following these awards, Malamut is shown with 28,012 directly held shares and an additional 1,040 shares indirectly held jointly with his spouse.
Plesha Scott M. reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. CEO and President Scott M. Plesha reported an equity compensation grant tied to restricted stock units. The Form 4 amendment shows an award of 83,678 shares of Common Stock, issuable upon settlement of RSUs granted under the company’s 2023 Equity Incentive Plan.
Each RSU represents one share of Common Stock and may be settled only in shares, subject to vesting. One-third of the RSUs vest on July 2, 2026, with the remaining balance vesting in equal quarterly installments over the following two years, contingent on continued service. Following this grant, Plesha holds 83,678 shares directly.
This filing amends a prior Form 4 by reclassifying the original RSU grant from the derivatives table to the non-derivative common stock table, clarifying how the award is reported rather than changing the underlying compensation terms.
Greenleaf Peter reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Peter Greenleaf reported an award of 25,478 shares of Common Stock, received as a grant of restricted stock units under the company’s 2023 Equity Incentive Plan. The award was granted as compensation for his service on the board of directors, at a stated price of $0.00 per share.
The RSUs vest over time: one-third of the underlying shares vested on July 2, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to continued service. Following this grant, Greenleaf directly holds 25,478 shares of Common Stock from this award.
Pauls Matthew reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Matthew Pauls reported an amended insider filing showing an equity award linked to 25,478 shares of common stock. These shares are issuable upon settlement of restricted stock units granted under the company’s 2023 Equity Incentive Plan as compensation for his board service.
The RSUs vest over time: one-third of the underlying shares vested on July 2, 2025, with the remaining units vesting in equal quarterly installments over two years, subject to his continued service. Following this grant, Pauls holds 25,478 shares of common stock directly.
Rangarao Sai reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. Chief Commercial Officer Rangarao Sai reported an amended insider filing reflecting an award of 30,518 shares of Common Stock, received as compensation in the form of restricted stock units (RSUs) under the company’s 2023 Equity Incentive Plan.
Each RSU represents the right to receive one share of Common Stock, settled solely in shares. One-third of the RSUs vests on July 2, 2026, with the remaining units vesting in equal quarterly installments over the following two years, contingent on Mr. Sai continuing in service. Following this grant, he directly holds 30,518 shares.
Baxter Richard B reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Richard B. Baxter reported an amended Form 4 reflecting a grant of 19,108 shares of Common Stock, issued at $0.00 per share upon settlement of previously granted restricted stock units (RSUs).
The RSUs were granted as compensation for his service on the board under the company’s 2023 Equity Incentive Plan. They vest in equal quarterly installments over three years, contingent on his continued service, and are settled solely in shares of Common Stock.
Francis Knuettel II reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. reported that its CFO, Treasurer and Secretary, Francis Knuettel II, received a grant of 33,472 restricted stock units (RSUs), each representing one share of common stock under the company’s 2023 Equity Incentive Plan. The RSUs were granted as compensation for his service as an officer and may be settled solely in shares of common stock, subject to vesting.
The RSUs vest with one-third of the shares on July 2, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, contingent on continued service. The filing also shows indirect holdings of common stock by Camden Capital LLC (10,000 shares) and the Lara Knuettel Revocable Trust (12,816 shares); Knuettel may be deemed to beneficially own these shares but disclaims beneficial ownership except for his pecuniary interest. Share amounts reflect a 1-for-10 reverse stock split effective July 1, 2025.
Pelthos Therapeutics Inc. reported its fourth-quarter and full-year 2025 results, showing a rapid commercial ramp for its lead product ZELSUVMI and expansion of its dermatology portfolio. ZELSUVMI net product revenue reached $16.2 million from launch in July 2025 through December 31, including $9.1 million in the fourth quarter, while total 2025 revenue including licensing was $16.8 million. Prescribers wrote 8,948 ZELSUVMI units in 2025 from 2,712 unique prescribers, with dispensed units rising 129% quarter over quarter. Pelthos acquired FDA‑approved XEPI for impetigo in November 2025 and XEGLYZE for head lice in January 2026, positioning a three-product pediatric-focused infectious skin franchise. To fund growth, the company closed an $18.0 million private convertible notes financing in November 2025 and entered a $50.0 million senior secured term loan in January 2026, drawing $30.0 million. Cash was $18.0 million as of December 31, 2025. Despite this progress, Pelthos reported a 2025 net loss of $43.3 million, including a $21.7 million loss in the fourth quarter, driven by high selling and administrative expenses, a non-cash $15.0 million fair value loss on convertible debt, and ongoing investments in commercialization.
Pelthos Therapeutics Inc. files its annual report describing a small, dermatology-focused biopharma built around recently acquired and launched products. The company was effectively formed through a July 1, 2025 merger between Channel Therapeutics Corporation and LNHC, Inc., gaining ZELSUVMI, a Durham, North Carolina API facility, and NaV1.7 pain assets.
Pelthos now has three FDA-approved products: ZELSUVMI for molluscum contagiosum, launched in July 2025; XEPI for impetigo, acquired in November 2025 and expected to relaunch in late 2026; and XEGLYZE for head lice, acquired in December 2025 with launch expected in 2027. ZELSUVMI is the first at-home prescription therapy for molluscum contagiosum and is central to the company’s near-term revenue plans.
The report highlights financing steps, including a Venture Loan and Security Agreement providing a senior secured term loan facility of up to $50.0 million, of which $30.0 million was borrowed on January 12, 2026, and a July 1, 2025 PIPE financing that raised approximately $50.1 million through 50,100 shares of Series A Preferred Stock at $1,000 per share. As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was approximately $6.7 million based on a $12.60 per share closing price, and 3,355,543 shares of common stock were outstanding as of March 11, 2026.
Management notes that the 2024 audit opinion contained a going concern qualification, while the 2025 opinion does not, but warns that failure to achieve sustainable revenues could still threaten the company’s ability to continue as a going concern. Extensive risk disclosures emphasize dependence on ZELSUVMI, challenges in building sales, marketing and market access, manufacturing and supply chain complexity around the NITRICIL nitric oxide platform, intense competition, regulatory and reimbursement uncertainty, data privacy obligations and thin trading liquidity in Pelthos common stock.
Pelthos Therapeutics Inc. received an amended Schedule 13G showing that investment adviser Ikarian Capital, LLC, together with its fund and certain managed accounts, beneficially owns 255,758 shares of common stock, or 8.4% of the company. This percentage is based on 3,235,543 shares outstanding as of November 7, 2025, as disclosed in a Form S-3. Ikarian Capital and its sole manager, Neil Shahrestani, may be deemed indirect beneficial owners through investment discretion, though each party includes customary disclaimers about beneficial ownership and group status. They certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Pelthos.